Bayer strengthens pharma portfolio with new cardiology drug acoramidis

Acquisition of exclusive commercialization rights for European markets

Lupin Digital Health and American College of Cardiology collaborate for in-home cardiovascular care in India

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022

Philips AI-powered interventional and diagnostic smart systems enhances diagnostic confidence, drive greater efficiency, and improve patient outcomes

Bayer acquires Attralus’ cardiac amyloidosis imaging agents

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology

Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM

The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics

World First: Heart bypass without opening the chest achieved by NIH and Emory Team

Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries

Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia

Abbott wins FDA & CE nod for groundbreaking premature infant heart device

The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds

Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai

India plays a critical role in Bristol Myers Squibb’s global strategy